The global bioinformatics market size was valued at USD 20.34 billion in 2025 and is projected to grow from USD 23.13 billion in 2026 to USD 64.59 billion by 2034, registering a CAGR of 13.7% during the forecast period from 2026 to 2034. North America dominated the bioinformatics market with a market share of 39.5% in 2025.
The field of bioinformatics combines biology and information technology. It connects biological data with information collection, distribution, and evaluation tools to serve numerous aspects of scientific research, such as biomedicine. It utilizes several software tools for database construction, data management, warehousing, and mining. Data mining yields scientific discoveries applied to the study of genetics and genomes.
Download a Free Sample To learn more about this report,
AI Is Transforming Bioinformatics From Data Analysis Into Predictive Biological Modeling
The growing volume of genomic, molecular, and clinical data is shifting bioinformatics from conventional data analysis toward AI-based prediction of biological processes, disease trajectories, and treatment outcomes. This transition enables bioinformatics platforms to combine multimodal datasets and identify complex patterns that are difficult to capture through individual analytical methods, supporting applications such as biomarker discovery and disease-risk modeling. In June 2026, the NIH reported that its All of Us Research Program provided data from more than 747,000 participants, including over 535,000 whole-genome sequences linked to nearly 482,000 electronic health records, creating a large-scale foundation for AI-driven biological modeling.
Multi-Omics Integration Is Expanding Beyond Single-Layer Genomic Analysis
The availability of genomic, transcriptomic, proteomic, metabolomic, and epigenomic data is shifting bioinformatics toward integrated multi-omics analysis rather than isolated genomic analysis. This transition gives researchers a broader molecular view of disease by connecting multiple biological layers, which supports biomarker identification, disease-subtype classification, and drug-target discovery. In 2026, NIH's All of Us dataset included proteomics data from nearly 10,000 participants and RNA sequencing data from nearly 9,000 participants, while its Multi-Omics for Health and Disease Consortium has received approximately $50.3 million over five years to develop scalable methods for generating and analyzing multi-omics datasets.
Pharmaceutical Drug Discovery and Cloud Infrastructure Drive Bioinformatics Market Growth
Pharmaceutical drug discovery activity creates demand for bioinformatics tools that analyze genomic, protein, molecular, and disease-related data during target identification and validation. AWS reports that AstraZeneca’s genomics data-processing solution runs 51 billion tests in one day, illustrating the scale of computational analysis used in pharmaceutical research.
Cloud infrastructure expands the supply of bioinformatics solutions by providing scalable computing and storage for organizations handling large genomic datasets. AWS HealthOmics can scale workflows across more than 100,000 concurrent vCPUs and supports storage of petabytes of genomics data, allowing research organizations to process large workloads without maintaining equivalent on-premise infrastructure.
High Costs and Skilled Professional Shortages Restrain Market Expansion
High bioinformatics infrastructure costs increase the investment required for computing systems, genomic data storage, specialized software, and data management. The resulting financial burden can delay technology investment among smaller laboratories and research institutions, limiting wider adoption of bioinformatics solutions.
A shortage of skilled bioinformatics professionals makes it difficult for organizations to manage complex genomic data, computational workflows, and specialized analytical platforms. Limited expertise can delay implementation and reduce the ability of research and healthcare organizations to scale bioinformatics applications.
Clinical Diagnostics and Microbiome Analysis Open Growth Opportunities
Clinical laboratories, diagnostic companies, and bioinformatics providers can develop genomic interpretation tools for disease identification and personalized diagnostics. Illumina reported $4.34 billion in 2025 revenue, with an active installed base of approximately 21,000 systems across 160+ countries, supporting opportunities for sequencing-linked bioinformatics and clinical interpretation solutions.
Biotechnology companies, microbiome research firms, and specialized bioinformatics providers can develop tools for microbial profiling and biological data interpretation. QIAGEN serves more than 500,000 customers worldwide and generated $2.09 billion in 2025 net sales, providing a broad commercial platform for microbiome workflows, molecular analysis, and related bioinformatics solutions.
Fragmented Data Standards and Inconsistent Metadata Hinder Bioinformatics Market Growth
Different metadata structures, file formats, and data standards make it difficult for bioinformatics platforms to integrate datasets across institutions and research environments. This limits seamless data reuse and can slow the expansion of solutions across diverse research workflows.
Poorly documented datasets reduce the ability of bioinformatics platforms to discover, compare, and reuse research data efficiently. A 2025 evaluation of 2,929 human gut microbiome studies found that nearly half did not meet minimum standards for sequence-data availability, demonstrating a practical barrier to reproducible data reuse and broader bioinformatics utilization.
The bioinformatics platforms segment dominated the bioinformatics market with a market share of 42.3% in 2025, valued at USD 8.6 billion, supported by the expanding use of computational platforms for genomic and biological data analysis. The segment is expected to grow at a CAGR of 13.6% during the forecast period 2026–2034.
The bioinformatics services segment is expected to register the fastest CAGR of 14.1% during the forecast period 2026–2034, reaching USD 5.94 billion. Its growth reflects the increasing use of specialized external capabilities for sequence analysis, database management, and complex biological data processing.
Request Customizationto receive a tailored report.
The genomics segment dominated the bioinformatics market by application with a market share of 27.5% in 2025, valued at USD 5.59 billion. Its position reflects the extensive computational requirements associated with sequencing, genomic interpretation, and analysis of large-scale genetic datasets.
The genomics segment is also expected to register the fastest CAGR of 14.6% during the forecast period 2026–2034. Transcriptomics and proteomics support analysis of gene expression and proteins, while chemoinformatics and drug design connect computational biological analysis with pharmaceutical research. Metabolomics and molecular phylogenetics serve specialized applications involving metabolic profiles and evolutionary relationships.
The medical bioinformatics segment dominated the bioinformatics market by sector with a market share of 46.2% in 2025, valued at USD 9.4 billion. Its large share is associated with the use of bioinformatics across clinical research, genomics, disease investigation, and other healthcare-related biological data applications.
The medical bioinformatics segment is expected to register the fastest CAGR of 14.3% during the forecast period 2026–2034. Agricultural bioinformatics supports crop and agricultural research, animal bioinformatics addresses biological and genetic analysis in animal applications, while academic institutions use bioinformatics for research and scientific education.
Speak to an Analystto discuss market opportunities.
North America dominated the global bioinformatics market with a 39.5% share in 2025, supported by established genomics research infrastructure, advanced computational capabilities, and strong activity across pharmaceutical, biotechnology, and academic research.
The U.S. bioinformatics market is supported by the NIH All of Us Research Program, which aims to gather health and genomic data from 1 million or more participants, creating a large-scale resource for genomic analysis, biomedical research, and precision medicine. The Canada bioinformatics market benefits from the Canadian Genomics Strategy, which provides CAD 175.1 million in federal funding over seven years from 2024–25, with priorities including improved genomics-data access, commercialization, and development of genomics capabilities.
Unlock Regional Insightsto access country-level data, & regional trends.
Europe is the fastest-growing region in the bioinformatics market, with a projected CAGR of 14.6% during the forecast period 2026-2034. Strong genomics research activity, personalized healthcare initiatives, and the integration of genomic technologies into clinical settings are increasing the demand for advanced biological data analysis.
The U.K. bioinformatics market is supported by plans for Genomics England to host more than 500,000 genomes by 2030, while its Adult Population Genomics Programme will sequence 150,000 adults, expanding the volume of genomic information requiring computational analysis. The genomDE initiative supports Germany's bioinformatics market, with a minimum five-year duration, and is designed to integrate genome sequencing into healthcare, creating sustained demand for genomic data infrastructure, computational analysis, and clinical interpretation.
Asia Pacific accounted for 22.4% of the global bioinformatics market share in 2025, supported by expanding biotechnology capabilities, genomic research programs, and greater use of biological data across pharmaceutical and life-science research.
The Japan bioinformatics market is supported by Japan’s 100,000 Whole Genome Analysis Plan, which has completed whole-genome analysis for 50,000 Japanese individuals and supports continued genomic-data generation for research and drug-development applications. The China bioinformatics market is being shaped by the country’s 2026–2030 development plan, which calls for wider application of digital and intelligent technologies in precision medicine, strengthening the role of bioinformatics, medical-data analysis, and AI-based genomic interpretation.
The India bioinformatics market is supported by the Department of Biotechnology’s BIO-GRID program, which is establishing or upgrading Bioinformatics and Computational Biology Centers covering areas such as genomics, transcriptomics, AI/ML in biology, computational drug discovery, and biological databases, aligned with India’s goal of becoming a global biotechnology hub by 2030.
The bioinformatics market is moderately fragmented, with competition comprising bioinformatics software providers, genomics and sequencing companies, cloud computing and data-platform providers, pharmaceutical and biotechnology technology firms, research institutions, and specialized computational biology solution providers. Leading players include Illumina, Agilent Technologies, Life Technologies (now part of Thermo Fisher Scientific), Affymetrix, and Bruker Daltonics.
Established players compete primarily on platform capabilities, data-processing performance, AI and machine-learning integration, interoperability, cybersecurity, scalability, regulatory compliance, technical support, and partnerships with pharmaceutical, biotechnology, and academic organizations, while emerging and regional players compete through specialized analytical tools, application-specific solutions, flexible deployment models, cost-efficient platforms, faster customization, and expertise in niche areas such as genomics, proteomics, and multi-omics analysis.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, and competitive dynamics.Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.
Healthcare Human Resources Software Market Size, Share, 2034
Critical Care Information Systems Market Size, Forecast, Demand, Opportunities, 2034
Meditation Management Apps Market Size, Share, Growth, Analysis, 2034
Cloud Based Drug Discovery Platform Market Size, Forecast, 2034
Computer Aided Drug Discovery Market Size, Forecast, Opportunities, 2034
Big Data in Healthcare Market Size, Share, Growth, Analysis, 2034
We are featured on:
sales@straitsresearch.com